Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PAM | P19021 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27276717 | 1.00 | CNR2 (0.66) | CNR2CNR1DGKALMNAPAM | |
| SCHEMBL27957521 | 1.00 | CNR2 (0.66) | CNR2CNR1DGKALMNAPAM | |
| SCHEMBL9577619 | 1.00 | CNR2 (0.66) | CNR2CNR1DGKALMNAPAM | |
| Ammonia Solution, Strong SCHEMBL27550393 | 0.96 | CNR2 (0.61) | CNR2CNR1DGKALMNAPAM | |
| SCHEMBL9348111 | 0.94 | CNR2 (0.68) | CNR2CNR1DGKALMNAPAM | |
| SCHEMBL10925926 | 0.94 | CNR2 (0.57) | CNR2CNR1DGKALMNAPAM | |
| SCHEMBL29255926 | 0.92 | CNR2 (0.66) | CNR2CNR1DGKALMNAPAM | |
| SCHEMBL20548310 | 0.92 | CNR2 (0.66) | CNR2CNR1DGKALMNAPAM | |
| SCHEMBL28442134 | 0.92 | CNR2 (0.66) | CNR2CNR1DGKALMNAPAM | |
| SCHEMBL29290670 | 0.92 | CNR2 (0.66) | CNR2CNR1DGKALMNAPAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106555331-A | A kind of antibiotic finishing solution and its application | 浙江安诺其助剂有限公司 | 2017-04-05 | — | — | CN | disclosed |
| EP-1892274-B1 | Water repellent treatment using polysiloxanes containing carboxyl groups | LANXESS DEUTSCHLAND GMBH (DE) | 2011-06-29 | — | — | EP | disclosed |
| EP-1108765-B1 | Hydrophobisation with carboxyl group containing polysiloxanes | LANXESS DEUTSCHLAND GMBH (DE) | 2009-07-08 | — | — | EP | disclosed |
| CN-101213266-A | Polyaspartic acid derivatives in covering agents containing polysiloxane | LANXESS DEUTSCHLAND GMBH (DE) | 2008-07-02 | — | — | CN | disclosed |
| EP-1904556-A2 | POLYASPARTIC ACID DERIVATIVES IN COVERING AGENTS CONTAINING POLYSILOXANE | Lanxess Deutschland GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1892274-A2 | Water repellent treatment using polysiloxanes containing carboxyl groups | Lanxess Deutschland GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2007003264-A2 | POLYASPARTIC ACID DERIVATIVES IN COVERING AGENTS CONTAINING POLYSILOXANE | LANXESS DEUTSCHLAND GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| EP-1518881-A2 | Polymer modified by a polyether as adjuvant in leather manufacture | Bayer Chemicals AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-20050058619-A1 | Polyether-modified polymers as leather auxiliaries | LANXESS DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
| EP-1263992-B1 | POLYSILOXANES USED FOR HYDROPHOBING | BAYER AG (DE) | 2003-10-22 | — | — | EP | disclosed |
| CN-1396958-A | Polysiloxanes used for hydrophobing | BAYER AG (DE) | 2003-02-12 | — | — | CN | disclosed |
| EP-1263992-A1 | POLYSILOXANES USED FOR HYDROPHOBING | Bayer Aktiengesellschaft (DE) | 2002-12-11 | — | — | EP | disclosed |
| EP-0842300-B1 | USE OF POLYASPARTIC ACID AMIDES AS LEATHER AUXILIARY PRODUCTS | BAYER AG (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001055456-A1 | POLYSILOXANES USED FOR HYDROPHOBING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-02 | — | — | WO | disclosed |
| EP-1108765-A2 | Hydrophobisation with carboxyl group containing polysiloxanes | BAYER AG (DE) | 2001-06-20 | — | — | EP | disclosed |
| US-5885474-A | TREATING LEATHER WITH MODIFIED POLYSUCCINIMIDE AND FIXING THE LEATHER BY ADDITION OF CHROMIUM, ALUMINUM, ZIRCONIUM OR TITANIUM COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| EP-0842300-A1 | USE OF POLYASPARTIC ACID AMIDES AS LEATHER AUXILIARY PRODUCTS | BAYER AG (DE) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997006279-A1 | USE OF POLYASPARTIC ACID AMIDES AS LEATHER AUXILIARY PRODUCTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058619-A1 | Polyether-modified polymers as leather auxiliaries | PUF60, B2M, CBR3 | CNR2 295/4885CNR1 571/4885DGKA 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.